carboplatin / Casp3 Cancer Research Results

carbop, carboplatin: Click to Expand ⟱
Features:
Carboplatin is a platinum-based chemotherapy drug, structurally related to cisplatin.
Advantages Over Cisplatin:
• Compared to cisplatin, carboplatin is associated with a more favorable side-effect profile, particularly with regard to reduced nephrotoxicity (renal toxicity).
• However, it may still cause bone marrow suppression, so careful monitoring of blood counts is essential.

Carboplatin is a key platinum-based chemotherapy agent that interferes with cancer cell DNA, leading to cell death. Its relatively favorable toxicity profile, compared to cisplatin, makes it a popular choice for treating a variety of solid tumors such as ovarian, lung, head and neck, bladder, and certain cases of testicular cancers. Due to its side-effect profile, particularly bone marrow suppression, patients receiving carboplatin require careful monitoring and dosage adjustments based on their renal function and other clinical factors.

Carboplatin — Carboplatin is a second-generation platinum coordination complex used as a cytotoxic antineoplastic. It functions primarily as a DNA-crosslinking platinum drug after intracellular activation by aquation, generating reactive platinum species that form covalent DNA adducts. It is formally classified as a platinum-based chemotherapy agent, often grouped with alkylating-like agents despite having distinct coordination chemistry. Standard abbreviations include CBDCA and the trade name Paraplatin. Clinically it is administered intravenously, usually by body-surface-area or Calvert AUC-based dosing, and is widely used in ovarian cancer and many platinum-containing combination regimens for lung and other solid tumors. Relative to cisplatin, carboplatin is generally less nephrotoxic, neurotoxic, and emetogenic, but its dominant dose-limiting toxicity is myelosuppression, especially thrombocytopenia and neutropenia.

Primary mechanisms (ranked):

  1. DNA platination with intra-strand and inter-strand crosslink formation, causing replication/transcription blockade
  2. DNA damage response activation with checkpoint signaling and p53-linked cell-fate engagement
  3. Apoptotic cell death following unrepaired platinum-DNA lesions
  4. Cytotoxic synergy with DNA repair deficiency or DNA repair inhibition
  5. Radiosensitization and chemosensitization in selected regimens
  6. Clinical resistance shaped by enhanced DNA repair, altered drug handling, and apoptotic evasion

Bioavailability / PK relevance: Carboplatin is not meaningfully orally bioavailable and is used intravenously. It is more chemically stable and aquates more slowly than cisplatin, which contributes to different toxicity kinetics. Clearance is strongly linked to renal function, making exposure-guided dosing clinically important; Calvert AUC-based dosing is standard in many settings. Systemic exposure is readily achievable because this is an approved infused cytotoxic, but therapeutic use is constrained by marrow toxicity rather than by poor delivery.

In-vitro vs systemic exposure relevance: Mechanism is concentration- and exposure-time-dependent, but unlike many phytochemicals, clinically relevant systemic exposure is achievable with standard infusion dosing. Even so, some in-vitro studies use prolonged or supra-clinical concentrations that may exaggerate secondary signaling effects relative to the core DNA-adduct mechanism seen in patients.

Clinical evidence status: Established standard-of-care cytotoxic chemotherapy with extensive human evidence and regulatory approval. Strongest formal label support is for ovarian carcinoma, while broader real-world and guideline-supported use includes multiple solid tumors in combination regimens. It is frequently used as backbone chemotherapy or as a substitute for cisplatin when toxicity profile or renal tolerance is limiting.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 DNA platinum adduct formation DNA intra-strand crosslinks ↑; DNA inter-strand crosslinks ↑; replication fork stress ↑ Same lesion class can occur in proliferating normal tissues P→R Core cytotoxic lesion generation Central mechanism. Carboplatin eventually forms DNA adduct classes similar to cisplatin, but with slower activation kinetics.
2 DNA damage response and checkpoint signaling ATM/ATR-p53 axis ↑; checkpoint arrest ↑; damage signaling ↑ DDR ↑ in exposed normal cells as well R→G Growth arrest and damage triage Cell-fate output depends on repair capacity, p53 context, and lesion burden.
3 Apoptosis BAX ↑; caspase activation ↑; apoptosis ↑; BCL-2 buffering may be overcome Marrow and other sensitive normal cells can also undergo apoptosis G Tumor cell kill This aligns with the limited Nestronics paper set showing Bax, p53, caspase-3, and apoptosis signals.
4 DNA repair dependency HR, NER, Fanconi-associated repair competence ↔/↑ resistance; repair deficiency ↑ sensitivity Normal tissue repair can mitigate injury R→G Major response determinant Clinical and translational relevance is high in ovarian cancer and other platinum-treated tumors.
5 Cell cycle arrest S-phase stress ↑; G2/M arrest ↑; proliferation ↓ Proliferating normal compartments may also slow R→G Anti-proliferative effect Not the initiating lesion, but a common downstream consequence of unresolved platinum damage.
6 Chemosensitization Combination efficacy ↑ with taxanes and selected DNA repair-targeting partners Normal tissue toxicity can also ↑ depending on regimen G Combination-regimen leverage Important clinically because carboplatin is commonly used as a backbone partner rather than as a stand-alone mechanistic probe.
7 Radiosensitization Radiation response ↑ (model-dependent) Normal tissue radiosensitivity may also ↑ R→G Adjunct cytotoxic amplification Relevant but secondary; useful in selected chemoradiation contexts rather than the primary identity of the drug.
8 Stemness and Wnt survival signaling ALDH1A1 ↓; Wnt/β-catenin ↓ (context-dependent) Unclear / limited direct relevance G Resistance-associated state modulation Supported on the Nestronics page, but this is better treated as context-dependent and not as a universal primary mechanism.
9 ROS and mitochondrial stress ROS ↑ (context-dependent) ROS ↑ can contribute to off-target injury R→G Secondary stress amplification Mechanistically plausible for platinum injury, but carboplatin is not best framed as a primary ROS drug. Keep secondary.
10 Clinical Translation Constraint Response limited by acquired resistance, tumor heterogeneity, and repair-adaptive survival Myelosuppression ↑; hypersensitivity risk ↑; renal function constrains dosing G Therapeutic window boundary Clinical utility is high, but marrow toxicity is the principal dose-limiting barrier and exposure must be matched to renal clearance.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
1300- GA,  PacT,  carbop,    Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line
- in-vitro, BC, MCF-7
TumCCA↑, Apoptosis↑, P53↑, BAX↑, Casp3↑, Bcl-2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:265  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page